Veranova invests $50 mn+ in ADC bioconjugation at Devens

Fibre2Fashion

17-06-2025

Veranova, a global leader in the development and manufacturing of specialist and complex active pharmaceutical ingredients (APIs) for the pharmaceutical and biotech sectors, today announced a strategic investment to establish state-of-the-art bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus.
Veranova is investing over $50 million to add bioconjugation development and cGMP manufacturing at its Devens, MA site, creating up to 70 jobs. The expansion, set for June 2026, will support ADCs and other bioconjugates, addressing rising demand for US-based biomanufacturing. It builds on Devens' expertise in complex synthesis and linker-payload production.
This expansion will enable Veranova to provide a more comprehensive suite of services to partners developing antibody-drug conjugates (ADCs) and other bioconjugates, and builds on the Devens facility's extensive experience in the development and clinical and commercial manufacture of ADC linker-payloads. Combined with a previously announced expansion of high-potent synthesis capacity in Devens, this will represent a more than $50 million investment into the site's capabilities for ADCs and other bioconjugates and will create up to 70 new jobs. The new capacity is planned to come online in June 2026.
The investment also addresses increasing demand for strong U.S.-based biomanufacturing capabilities and will help U.S.-based customers secure domestic supply chains for critical drug substances.
The bioconjugation expansion will include new process and analytical development laboratories, grade C cleanroom space, development and cGMP equipment and instrumentation, and supporting infrastructure. These capabilities will support up to kilogram-scale manufacturing of potent and non-potent bioconjugates.
'We continue to see ADCs and other conjugated molecules as a key growth area as our customers look to develop more targeted therapies,' said Mike Riley, CEO of Veranova. 'This investment will build on our core capabilities in complex chemistry, analytics and linker-payload synthesis, and leverage our strategically located cGMP infrastructure to provide a differentiated solution to our customers.'
The Devens site is a key location in Veranova's global manufacturing network, situated in close proximity to the Boston-Cambridge biotechnology hub. The site has over 15 years of experience in the development and manufacture of linker-payloads and other complex synthetic molecules supported by expertise in complex synthesis, analytical development and testing, high potent handling, crystallization development, and chromatography purification. Veranova Devens is an FDA-approved facility with capabilities spanning early process and analytical development, scale-up, and clinical and commercial manufacturing under one roof. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged.
Fibre2Fashion News Desk (HU)